Prime editing made more than 175 DNA edits in human cells
Researchers made more than 175 edits in human cells using prime editing, a method that writes changes into DNA without requiring breaks across both strands or a separate DNA replacement template. Published in Nature on 21 October 2019, the study demonstrated targeted insertions and deletions, along with all 12 types of point mutation, changes to individual DNA letters. The team also used the method to correct the primary genetic causes of sickle cell disease and Tay-Sachs disease in human cells, efficiently and with few unwanted editing products.
Prime editing joined a Cas9 enzyme with impaired DNA-cutting activity to an engineered reverse transcriptase, an enzyme that copies instructions from RNA into DNA. A prime editing guide RNA, or pegRNA, directed this machinery to a specified DNA location and carried the instructions for the desired change.
Correcting the sickle cell disease variant required a transversion, a type of DNA-letter substitution, in HBB. For Tay-Sachs disease, the team deleted DNA in HEXA. The researchers also installed a transversion in PRNP that they described as protective, and precisely inserted tags and epitopes, recognition markers, at specified DNA locations.
The method worked in four human cell lines and in mouse cortical neurons, brain cells that had stopped dividing. Its efficiency varied across those cells. Compared with homology-directed repair, a DNA repair process used in editing, prime editing had higher or similar efficiency and produced fewer unwanted editing products. The authors reported complementary strengths and weaknesses compared to base editing, rather than an advantage across the board. Prime editing also caused much less editing at known unintended Cas9 target sites than Cas9 nuclease did.
The authors estimated that prime editing could, in principle, correct up to 89% of known genetic variants associated with human diseases. That figure described the potential range of changes the method could address. It was not the proportion of disease-associated variants corrected in the experiments.